US EditionPeatonide may halve migraine incidence and duration
Summary by nutraingredients.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Peatonide may halve migraine incidence and duration
A study published in Frontiers in Nutrition suggests that Peatonide, a supplement combining palmitoylethanolamide (PEA) and melatonin, may reduce migraine frequency, duration and intensity by at least 50% after three months of treatment. This approach could offer a promising alternative to traditional migraine medications with fewer side effects according to researchers.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage